153 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
, he held positions at pharmaceutical companies such as IDM Pharma, Inc., Takeda Global Research and Development, NeoPharm Inc., G.D. Searle, LLC … was at Teva Pharmaceutical Industries in various roles, including being responsible for research and development and public policy in North America from
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
, or $0.30 per share, compared to a net loss of $9.4 million, or $0.21 per share, for the fourth quarter of 2022.
Research and development expenses … for the fourth quarter of 2023 were $10.6 million compared to $7.2 million for the fourth quarter of 2022. The increase in research and development
8-K
EX-99.3
LRMR
Larimar Therapeutics Inc
11 Mar 24
Other Events
4:09pm
and commercialize nomlabofusp (CTI-1601) and other planned product candidates, Larimar’s planned research and development efforts, including the timing of its
8-K
EX-99.1
jv24hehei7
11 Mar 24
Other Events
4:09pm
8-K
EX-99.2
yiipa4vbnr
11 Mar 24
Other Events
4:09pm
424B5
wye07thr
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
bvy 4crccjefex6p
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
9v2dj16y08r0 gz
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.3
u174wsx130u 8a
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
6t9sip ysy
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
cx8ak7
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.2
4x8glf5f brzt
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
2rhe3c63i1cz0sn fef6
3 Oct 23
Departure of Directors or Certain Officers
4:31pm
8-K
EX-99.1
iglr9n
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
fq2kyjno
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am